Soleno Therapeutics (SLNO) announced that its Board of Directors has authorized a share repurchase and that it has entered into an Accelerated Share Repurchase Agreement with Jefferies to repurchase $100 million of Soleno’s common stock.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO:
- Soleno Therapeutics: Strong Q3 Performance and Market Potential Justify Buy Rating
- Soleno Therapeutics’ Financial Challenges: Navigating Risks in VYKAT XR Commercialization
- Soleno Therapeutics’ Earnings Call Highlights Growth Amid Challenges
- Midday Fly By: Broader market bought on dip after tech selloff
- Soleno Therapeutics falls -29.0%